Selenomethionine (SLM)

DRUG2 trials

Sponsors

Mohammed Milhem

Conditions

Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)Clear Cell Renal Cell CarcinomaClear Cell Renal Cell Carcinoma Metastatic

Phase 1

SLM + Axitinib for Clear Cell RCC

CompletedNCT02535533

Mohammed MilhemAdvanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)

Start: 2016-01-01End: 2025-04-04Updated: 2026-05-06

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Active, not recruitingNCT05363631

Mohammed MilhemClear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic

Start: 2022-09-19End: 2026-12-31Target: 55Updated: 2025-12-10

Related Papers

Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside.

Journal of Clinical Oncology2021-02-201 citations

Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.

Journal of Clinical Oncology2019-03-015 citations

Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.

Journal of Clinical Oncology2018-02-209 citations